Neurogenics Therapeutics

Neurogenics Therapeutics is a preclinical-stage biotechnology company dedicated to developing transformative gene therapies for neurodegenerative disorders, with a primary focus on Alzheimer's disease. Founded by Dr. Mark Tuszynski, a pioneer in neurobiology, the company leverages decades of research into neurotrophic factors to restore neuronal function and prevent cell death. Its lead programs utilize adeno-associated virus (AAV) vectors to deliver Nerve Growth Factor (NGF) and Brain-Derived Neurotrophic Factor (BDNF) directly to affected brain regions. By targeting the underlying mechanisms of neurodegeneration rather than just symptoms, Neurogenics aims to provide long-lasting therapeutic benefits for patients with limited treatment options. The company is currently advancing its pipeline through preclinical studies to support future clinical development.